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Abstract
Glioblastoma (GBM) and other malignant gliomas are aggressive primary neoplasms of the brain that exhibit notable
refractivity to standard treatment regimens. Recent large-scale molecular profiling has revealed distinct disease subclasses
within malignant gliomas whose defining genomic features highlight dysregulated molecular networks as potential targets
for therapeutic development. The ‘‘proneural’’ designation represents the largest and most heterogeneous of these
subclasses, and includes both a large fraction of GBMs along with most of their lower-grade astrocytic and oligodendroglial
counterparts. The pathogenesis of proneural gliomas has been repeatedly associated with dysregulated PDGF signaling.
Nevertheless, genomic amplification or activating mutations involving the PDGF receptor (PDGFRA) characterize only a
subset of proneural GBMs, while the mechanisms driving dysregulated PDGF signaling and downstream oncogenic
networks in remaining tumors are unclear. MicroRNAs (miRNAs) are a class of small, noncoding RNAs that regulate gene
expression by binding loosely complimentary sequences in target mRNAs. The role of miRNA biology in numerous cancer
variants is well established. In an analysis of miRNA involvement in the phenotypic expression and regulation of oncogenic
PDGF signaling, we found that miR-34a is downregulated by PDGF pathway activation in vitro. Similarly, analysis of data
from the Cancer Genome Atlas (TCGA) revealed that miR-34a expression is significantly lower in proneural gliomas
compared to other tumor subtypes. Using primary GBM cells maintained under neurosphere conditions, we then
demonstrated that miR-34a specifically affects growth of proneural glioma cells in vitro and in vivo. Further bioinformatic
analysis identified PDGFRA as a direct target of miR-34a and this interaction was experimentally validated. Finally, we found
that PDGF-driven miR-34a repression is unlikely to operate solely through a p53-dependent mechanism. Taken together,
our data support the existence of reciprocal negative feedback regulation involving miR-34 and PDGFRA expression in
proneural gliomas and, as such, identify a subtype specific therapeutic potential for miR-34a.
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Introduction
Malignant gliomas—particularly glioblastoma (GBM), the most
common and aggressive adult variant—continue to cause a
disproportionate degree of morbidity and mortality within human
oncology and remain soberingly refractive to conventional
therapeutic options [1]. Recent integrated genomics has convinc-
ingly demonstrated biologically distinct subclasses within malig-
nant glioma that transcend conventional histopathological bound-
aries, with each characterized by differing patterns of driving
molecular abnormalities [2,3,4]. Perhaps the broadest of these
subclasses has been termed ‘‘proneural’’ and includes both a large
fraction of GBMs along with most of their lower-grade astrocytic
and oligodendroglial counterparts. The pathogenesis of proneural
gliomas has been strongly linked to dysregulated PDGF signaling
and the activation of downstream oncogenic signaling networks
[4]. And while amplification or activating mutations involving the
PDGF receptor gene (PDGFRA) characterize a significant subset of
proneural GBMs [3,4], alternative non-genomic mechanisms
driving PDGF signaling, particularly in lower-grade tumors,
remain unclear. In such cases, the involvement of epigenomic
and/or pretranslational regulatory systems seems likely.
miRNAs are short (,22 nucleotide) single stranded RNAs that
repress gene expression by binding loosely complementary
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33844sequences in the 39-untranslated regions (39-UTRs) of target
mRNAs [5]. Each miRNA likely interacts with numerous mRNA
transcripts, a promiscuity that speaks to the potential of individual
miRNAs to serve as ‘‘master regulators’’ mediating complex
biological phenotypes [6]. Nevertheless, the relative importance of
specific miRNA/mRNA interactions can depend heavily on
physiological and cellular context, underscoring the absolute
necessity of tissue and disease-specific experimental validation.
Many research groups, including our own, have directly
implicated a number of specific miRNAs in the pathogenesis of
malignant glioma, both as tumor suppressors and oncogenes [7].
Furthermore, miRNA signatures have recently been demonstrated
to stratify GBMs into defined biological subclasses, with each
demonstrating intriguing links to distinct cellular lineages within
the central nervous system [8].
We sought to identify and characterize biologically relevant
miRNA-mediated regulatory networks involved in proneural
gliomagenesis. In this report, we use a combination of experi-
mental and computational methodologies to demonstrate that
miR-34a is downregulated by oncogenic PDGF signaling, and that
its expression level is negatively correlated with proneural subclass
in GBM. We then show that miR-34a specifically inhibits growth
in proneural glioma cells both in vitro and in vivo and identify
PDGFRA as a direct and functionally consequential miR-34a
target. Finally, we demonstrate that the regulation of miR-34a
expression by PDGF signaling likely operates through a p53-
independent mechanism. Our findings thus identify a reciprocal
negative feedback loop influencing oncogenic receptor tyrosine
kinase (RTK) signaling whose fundamental dysregulation in
proneural gliomas contributes to tumorigenesis.
Results
miR-34a is downregulated in proneural GBMs and in
response to activated PDGF signaling
Given the central role likely played by dysregulated PDGF
signaling in proneural gliomagenesis, we wanted to identify
miRNAs whose expression levels responded to changes in pathway
activation status. To do this, we utilized an NIH-3T3 cell line
harboring a unique fusion protein (KP) composed of the
extracellular domain of KDR (VEGF receptor II) and the
intracellular domain of PDGFRA [9]. KP overexpression
morphologically and functionally transforms NIH-3T3 cells in a
manner that is completely reversible by pharmacological inhibi-
tion with imatinib. Profiling of KP-expressing NIH-3T3 cells
revealed a number of miRNAs whose expression levels varied in
response to oncogenic PDGF signaling. Among the most
significantly downregulated miRNA species was miR-34a, whose
repression was completely reversible with imatinib treatment
(FIG. 1A). Additionally, we found that neither of the miR-34a
homologues miR-34b and -34c exhibited statistically significant
expression changes in this experimental paradigm (data not
shown). These findings indicated that dysregulated PDGF
signaling selectively represses miR-34a. To determine whether
miR-34a is also specifically downregulated in proneural GBMs we
analyzed publically available miRNA expression data from 191
primary GBMs profiled by the Cancer Genome Atlas (TCGA).
We found that miR-34a levels exhibited a strong negative
correlation with proneural subclass (P=1.2610
212; FIG. 1B–
1C). Once again, miR-34b and -34c failed to exhibit similarly
robust associations (FIG. 1B). Coupled with our KP cell line data,
these findings indicate that miR-34a is selectively downregulated
in proneural GBMs, likely in response to oncogenic PDGF
signaling.
miR-34a specifically inhibits proliferation and
tumorigenesis in proneural glioma cells
To determine the functional importance of miR-34a downreg-
ulation in proneural malignant gliomas, we restored its expression
in three human glioma cell lines cultured as neurospheres in stem-
like conditions (TS543, TS667, and TS600). Prior array-
comparative genomic hybridization (aCGH) had demonstrated
focal PDGRA amplification (chromosome 4q) in both TS543 and
TS667 cell lines (FIG. 2A), and each demonstrated strong
proneural character as determined by validated transcriptional
analysis (Huse, J.T., Kastenhuber, E.R, and Brennan, C.W.,
unpublished work). By contrast, TS600 was characterized by
EGFR amplification (chromosome 7p) by aCGH (FIG. 2A) and
mesenchymal subclass by expression analysis. Exogenously driven
miR-34a expression significantly slowed proliferation in both
TS543 and TS667 cells, but not TS600 cells as assessed by MTT
assay (FIG. 2B). Furthermore, robust miR-34a overexpression in
these experiments was validated in both responsive (TS543) and
unresponsive (TS600) cell lines (FIG. S1). These findings reveal a
selective inhibitory capability of miR-34a on cell proliferation that
is largely restricted to proneural subclass.
To more precisely determine the biological impact of miR-34a
on proneural gliomagenesis, we performed cell cycle distribution
analysis on TS543 cells pulsed with BrdU. We found that miR-34a
transfection markedly decreased the number of cells in S-phase by
39% (P,0.05) with a concomitant increase in the number of cells
in G0/G1, relative to both control oligonucleotide and mock
transfection (FIG. 3A). We also evaluated the effect of miR-34a on
apoptosis induction but did not observe any increase in annexin V
staining in miR-34a transfected TS543 cells (FIG. 3B). Finally, to
probe the functional relevance of miR-34a to proneural
gliomagenesis in vivo, we xenografted either miR-34a or control
oligonucleotide transfected TS543 cells into the brains of ICR scid
mice. A stably expressed luciferase construct allowed for
monitoring of tumor growth by luminescence. This analysis
revealed a significant inhibitory effect of miR-34a on tumor
formation (64% reduction in tumor size, P,0.05) over the course
of 11 days (FIG. 3C). Taken together, our data indicate that miR-
34a represses proneural gliomagenesis both in vitro and in vivo,
primarily by interfering with cell cycle progression.
miR-34a directly targets PDGFRA transcript to facilitate
proneural gliomagenesis
To identify potential targets of miR-34a, we again utilized
integrated molecular profiling data from TCGA, this time
selecting mRNAs predicted to interact with miR-34a whose
expression was also anticorrelated with that of the miRNA. In
parallel, we also performed transcriptional profiling on TS543
cells, focusing on mRNAs whose levels decreased in response to
miR-34a transfection as compared to control oligonucleotide.
Plotting these results orthogonally to each other revealed
PDGFRA transcript as one of the most negatively correlated
mRNA candidates by this combined analysis, consistent with a
direct miRNA/mRNA regulatory interaction (FIG. 4A). Perhaps
not surprisingly, when the reciprocal relationship of miR-34a and
PDGFRA was examined for all TCGA tumors after expression
subclass stratification, PDGFRA levels were highest in proneural
GBMs (FIG. 4B).
Examination of the PDGFRA 39 UTR revealed two potential
evolutionary conserved binding sites for miR-34a (FIG. 4C). To
determine whether miR-34a directly represses PDGFRA mRNA,
we performed western blots on lysates from TS543 cells
transfected with either miR-34a or control oligonucleotide and
Repression of PDGFRA-Targeting miR-34a in Gliomas
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33844found a dramatic decrease in PDGFRA protein levels associated
with miR-34a overexpression (FIG. 4D). To confirm that miR-34a
directly complexes with PDGFRA transcript, we cloned the
segment of its 39 UTR harboring these two binding sites
downstream of a luciferase reporter cassette and expressed the
resulting plasmid in TS543 cells. Co-transfection with miR-34a
resulted in a significant 57% decrease (P,0.0001) in luminescence
relative to a control oligonucleotide (FIG. 4E). Moreover, an
analogous experiment utilizing the parental luciferase reporter
construct not containing the PDGFRA 39 UTR segment failed to
demonstrate reduced luminescence in response to miR-34a
overexpression. These findings confirm miR-34a regulates
PDGFRA transcript through direct interactions with its 39 UTR.
Several additional miR-34a targets have been reported thus far
in a variety of cell and tissue types. Specifically in the context of
malignant glioma, these include NOTCH1, NOTCH2, MET,
and CDK6 [10]. To evaluate whether miR-34a-mediated
regulation of these targets contributes to the miRNA’s functional
impact on proneural gliomagenesis, we performed western blots in
miR-34a and control oligonucleotide transfected TS543 cells. We
Figure 1. miR-34a is selectively downregulated in proneural glioma, likely in response to activated PDGF signaling. A) RNA was
extracted from KP cells treated with DMSO control, KP cells treated with imatinib for 72 hours, and parental NIH 3T3 cells treated with DMSO control.
miRNA expression profiling identified miR-34a as being responsive to PDGF signaling. B) Data from TCGA demonstrate a strong negative correlation
of miR-34a with proneural subclass. C) Expression of miR-34a in proneural gliomas and in gliomas of other subtypes. *, P,0.05. **, P,0.005.
***, P=1e-12.
doi:10.1371/journal.pone.0033844.g001
Figure 2. miR-34a specifically inhibits proliferation of proneural glioma cells. A) aCGH analyses of cell lines used. Proneural TS543 and
TS667 cells both harbor PDGFRA amplification on chromosome 4, and mesenchymal TS600 cells harbor EGFR amplification on chromosome 7. B)
Cells were transiently transfected with miR-34a mimics or control oligonucleotides and for assayed cell numbers over 3–8 days by MTT assay.
doi:10.1371/journal.pone.0033844.g002
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repressive effects on NOTCH1, with NOTCH2, MET, and
CDK6 levels essentially remaining unchanged (FIG. 5A and S2).
To determine the extent to which selective PDGFRA and
NOTCH1 repression recapitulates to the biological effects of
miR-34a in proneural glioma, we transfected TS543 cells with
siRNAs specific for either mRNA target and monitored cell
proliferation by S-phase BrdU incorporation (FIG. 5B). In this
experimental context, only PDGFRA knockdown reduced BrdU
uptake (37% reduction, P,0.05) comparably to miR-34a
overexpression (60% reduction, P,0.005), with NOTCH1
knockdown having no observable effect. These findings demon-
strate that PDGFRA repression by miR-34a promotes proneural
gliomagenesis and, furthermore, suggest that the PDGFRA
represents the most functionally consequential miR-34a target.
miR-34a repression in proneural gliomas is only modestly
dependent on p53
Several reports have shown that miR-34a is transcriptionally
activated by p53 [11,12,13,14]. To determine if miR-34a
downregulation in proneural gliomas is p53-dependent, we once
again applied both bioinformatic and experimental approaches.
Integrating expression and genomic data from TCGA, we found
significantly reduced miR-34a expression in proneural GBMs
compared to those of other subclasses irrespective of p53 genomic
status (P,0.0001; FIG. 6A). While miR-34a levels were somewhat
lower in p53-mutant proneural tumors compared to their p53-wild
type counterparts (P=0.048), the impact of proneural molecular
subclass on miR-34a expression clearly predominated. We also
utilized the KP NIH-3T3 system to assess whether PDGF-induced
miR-34a repression is dependent on p53. Activated PI3K/AKT
signaling, a canonical effector pathway mobilized by RTKs like
PDGFRA, has been shown to induce p53 degradation through
phosphorylation of MDM2 [15]. In KP expressing cells, we found
high-levels of both p-AKT and p-MDM2 by western blot that
were each suppressed with imatinib, consistent with earlier reports.
However, somewhat surprisingly, we were not able to demonstrate
any change in p53 expression across multiple time points (FIG. 6B).
These results, coupled with our bioinformatic data, indicate that
p53 exerts, at best, only a modest effect on miR-34a expression in
proneural gliomas.
Discussion
The ineffectiveness of standard therapies in the treatment of
malignant gliomas signals an urgent need for the development of
disease-relevant targeted agents. This process itself requires a more
complete understanding of underlying glioma biology, particularly
with regard to its well-established variability at the molecular level.
Several miRNA-mediated networks have been directly implicated
in gliomagenesis, and recent work has shown that robust miRNA
signatures designate distinct GBM subclasses, highlighting the
relevance of miRNA biology to the analysis of molecular
heterogeneity in malignant glioma [7,8]. In the present study,
we aimed to identify and characterize miRNAs involved in the
pathogenesis of proneural gliomas using an approach that
repeatedly combined in vitro methodologies with existing bioinfor-
matic resources. As such, the ready availability of TCGA profiling
data for GBM was an essential component of our basic strategy.
Our findings indicate that proneural gliomas are specifically
characterized by miR-34a downregulation with subsequent
derepression of the miRNA’s downstream target PDGFRA, a
process that promotes tumorigenesis both in vitro and in vivo. The
restriction of this regulatory interaction to proneural gliomas is
perhaps not surprising given the highly distinctive molecular
profiles exhibited by different GBM expression subclasses, and the
central role of PDGFRA in proneural gliomagenesis. miRNA
behavior and target profiles are known to be highly dependent on
cellular context. Indeed, specific miRNAs have even been shown
to behave as both oncogenes and tumor suppressors in different
cancer variants [16].
miR-34a was originally identified as a likely tumor suppressor
miRNA and a downstream transcriptional target of p53
[11,12,13,14]. Prior reports have shown that miR-34a is
downregulated in GBM compared to normal brain, and that it
Figure 3. miR-34a induces cell cycle arrest and inhibits tumorigenesis in proneural GBM cells. A) 48 hours post-transfection, proneural
TS543 were pulsed with BrdU and assayed for cell cycle distribution and B) apoptosis by Annexin V flow cytometry. Staurosporine was added as
positive control. C) Ex vivo-transfected TS453 cells stably expressing a luciferase reporter plasmid were xenografted into the brains of ICR scid mice
and tumor formation and growth was followed over 11 days. Error bars represent standard deviation within a single experimental set containing
multiple replicates. Similar results were obtained in at least 3 independent experiments. *, P,0.05. **, P,0.005.
doi:10.1371/journal.pone.0033844.g003
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glioma cell lines by targeting MET, NOTCH1, NOTCH2, and
CDK6 [10]. Additionally, miR-34a appears to promote differen-
tiation in glioma cells grown in stem-like conditions [17]. Our
findings indicate that PDGFRA represents a crucial target of miR-
34a in the setting of proneural gliomagenesis. Our examination of
other transcripts known to interact with miR-34a in GBM
revealed that only NOTCH1 was significantly repressed by the
miRNA in bona fide proneural glioma cells. Moreover, specific
siRNA knockdown of NOTCH1 failed to demonstrate functional
consequences, while PDGFRA knockdown yielded significantly
reduced BrdU incorporation, emphasizing functional relevance.
Nevertheless, we anticipate that other important miR-34a targets
remain to be identified, particularly given that selective PDGFRA
knockdown does not fully recapitulate the effects of miR-34a on
cell proliferation in proneural glioma cells.
miR-34a repression in proneural gliomas appears to result
directly from enhanced PDGF signaling. We found that
constitutive activity in the PDGF pathway directly downregulates
miR-34a expression in a manner that is completely reversible by
imatinib administration. The well-established role of p53 in the
transcriptional activation of miR-34a prompted us to investigate
whether miR-34a repression in proneural gliomas is mediated
through a p53-dependent mechanism. Indeed, earlier work has
identified a potential conduit for such transcriptional regulation
through p-AKT and p-MDM2 [15]. However, our western blot
analysis in proneural TS543 cells failed to demonstrate significant
changes in p53 levels in response to imatinib, despite robust
modulation of both p-AKT and p-MDM2 levels. These finding
indicate, somewhat surprisingly, that upstream regulation of miR-
34a is, at best, only partially regulated by a p53-dependent
mechanism and that alternative molecular pathways are likely
involved in proneural GBMs. Consistent with this conjecture are
TCGA data demonstrating that proneural subclass, rather than
p53 genomic status, is most predictive of miR-34a expression
levels. Additionally, the fact that miR-34b and -34c, which are also
regulated by p53 [12], are not similarly repressed by dysregulated
PDGF signaling provides further support for the contribution of
p53-independent mechanisms.
In summary, we identify a miRNA-mediated network that
promotes tumorigenesis in a specific glioma subtype by deregu-
lating that subtype’s single most defining oncogenic driver.
Disrupting the homeostatic equilibrium between miR-34a and
PDGFRA potentially gives rise to a cancer-promoting, feed-
Figure 4. miR-34a targets PDGFRA. A) Scatter plot showing expression change (quantified by a moderated t-statistic) following miR-34a
overexpression in TS543 cells and correlation with miR-34a expression in TCGA GBM tumors (Spearman correlation) for all miR-34a predicted mRNA
targets. PDGFRA mRNA is highlighted in red. B) Integrated molecular profiling data from TCGA show that PDGFRA transcript exhibits a negative
association with miR-34a. Expression subclasses are indicated (proneural-red, neural-blue, mesenchymal-green, and classical-purple). C) The two
predicted miR-34a binding sites in the 39 UTR of PDGFRA. D) TS543 cells were transfected with either miR-34a or control oligonucleotides for
24 hours, and PDGFRA protein levels were measured by immunoblotting. E) miR-34a was co-transfected with a PDGFRA 39 UTR luciferase reporter
construct into TS543 cells and assayed for luciferase 24 hours post-transfection. As a control, the parental luciferase reporter construct not containing
the PDGFRA 39 UTR segment was used in parallel studies. Error bars represent standard deviation within a single experimental set containing multiple
replicates. Similar results were obtained in at least 3 independent experiments. ***, P,0.0001.
doi:10.1371/journal.pone.0033844.g004
Repression of PDGFRA-Targeting miR-34a in Gliomas
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33844forward loop, one that could ultimately lead to both cell
proliferation and tumor formation. Intriguingly, such a mecha-
nism could conceivably drive gliomagenesis even in the absence of
canonical genomic aberrations (e.g. mutations or copy number
gains) in core signaling pathway components. This consideration is
particularly relevant to proneural gliomas, which, despite their
strong associations with dysregulated PDGF signaling, only harbor
mutations and or amplifications of PDGFRA in a minority of
cases. On a related note, these findings also serve to further
emphasize the therapeutic potential of inhibiting PDGF signaling
in the proneural subtype of malignant glioma.
Materials and Methods
Ethics statement
Primary GBM samples were obtained after approval by the
Memorial Sloan-Kettering Cancer Center Institutional Review
Board under the auspices of an existing blanket tissue collection
protocol after written informed consent. This study was performed
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health. Animal experiments were conducted using protocols
approved by the Institutional Animal Care and Use Committee of
Memorial Sloan-Kettering Cancer Center (Protocol 09-09-017).
Chemicals, miRNA- and siRNA-oligonucleotides
Imatinib was purchased from LC laboratories (Woburn, MA).
Staurosporine was from Sigma-Aldrich (St. Louis, MO). miR-
IDIAN miRNA mimic negative controls #1 and #2, miRIDIAN
miRNA mimics (hsa-miR-34a), PDGFRA and NOTCH1 target-
ing ON-TARGETplus SMARTpool siRNAs and control were
purchased from Dharmacon (Lafayette, CO).
Quantitative reverse transcriptase polymerase chain
reaction
Total RNA was extracted using the miR-Vana RNA isolation
system (Applied Biosystems, Foster City CA). Expression of miR-
34a was measured using TaqManH miRNA assays system (Applied
Biosystems, Foster City, CA) according to the manufacture’s
instruction. RNU6B was used as endogenous control.
Copy number assessment in glioma cell lines
Genomic DNA was extracted from primary tumors using
standard techniques. DNA was then digested and labeled and
hybridized to 244K CGH arrays according to manufacturer
guidelines (Genomic DNA labeling kit PLUS, Agilent, Santa
Clara, CA). Normal male genomic DNA (Promega, Madison, WI)
was used as a reference. Array scanning, segmentation of raw data,
and plotting was performed as previously described [4].
Cell culture and transfections
NIH 3T3 cells and NIH3T3 cells expressing the KDR-
PFGFRA (KP) fusion protein were obtained as previously
described [9]. KP and control NIH 3T3 cells were cultured under
5% CO2 at 37uC in Dulbecco’s Modified Eagle’s medium (ATCC:
30-2002) with 10% heat-inactivated calf serum (Colorado Serum
Co. Denver, CO). Tumor sphere (TS) cells were isolated from
primary human glioblastomas by disassociation into single cell
suspension using Accumax (Innovative Cell Technologies, San
Diego, CA) as previously described. Cells were filtered through a
100 mm filter, and plated in NeuroCult NS-A proliferation media
(Stem Cell Technologies, Vancouver, BC) supplemented with
EGF (20 ng/ml; R&D Systems, Minneapolis, MN), FGF (10 ng/
ml; Peprotech, Rocky Hill, NJ), and heparin (2 mg/ml, Stem Cell
Technologies, Vancouver, BC). Oligonucleotides were transfected
to a final concentration of 100 nM using the HiPerFect
Transfection Reagent (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Imatinib/Gleevec treatment of KP
NIH 3T3 cells were performed at 10 uM.
Proliferation assays, cell cycle analysis, and apoptosis
assays
The CellTiter-GloH Luminescent Cell Viability Assay (Pro-
mega, Madison, WI) was used according to the manufacturer’s
instructions to estimate cell numbers. Cell cycle analyses were
Figure 5. PDGFRA represents the most functionally conse-
quential miR -34a target. A) TS543 cells were transfected with either
miR-34a or control oligonucleotides for 24 hours, and NOTCH1 protein
levels were measured by immunoblotting. B) 48 hours post-transfec-
tion, TS543 cells transfected with either miR-34a, siRNAs against
PDGFRA, siRNAs against NOTCH1, or control oligonucleotides were
pulsed with BrdU and assayed for cell proliferation by S-phase BrdU
incorporation. siRNAs against PDGFRA and NOTCH1 are effective at
reducing PDGFRA and NOTCH1 protein levels, respectively, as
measured by immunoblotting 24 hours post-transfection. Error bars
represent standard deviation within a single experimental set
containing multiple replicates. Similar results were obtained in at least
3 independent experiments. *, P,0.05. **, P,0.005.
doi:10.1371/journal.pone.0033844.g005
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following the manufacturer’s recommendations (BD Pharmingen,
San Diego, CA) as previously described [18]. Apoptotic cells were
identified using Annexin-V-FLUOS Staining Kit (Roche, Mann-
heim, Germany) following the manufacturer’s protocol. Stauros-
porine, 300 nM overnight was used as a positive control to induce
apoptosis in TS543 cells. All flow analyses were performed 48 h
post-transfection.
Animal experiments
ICR scid (Taconic Farms Inc, Hudson, NY) 5–6 week old male
mice were anesthetized with intraperitoneal injections of ketamine
(0.15 mg/g) and xylazine (0.015 mg/g). An electric razor was used
to shave the top of the head and the area was cleaned using
alcohol and betadine. Scalps were sagittally incised to expose the
skull, and a 1 mm burr hole was drilled in the skull. Injections into
the subventricular zone (SVZ) were performed using a stereotactic
fixation device (Kopf Instruments, Tujunga, CA, model 963). Two
microliters of 1–2610
4 transfected TS543 cell suspension was
delivered into the right hemisphere using a Hamilton syringe
(Hamilton, Reno, NV catalog # 87930) over 2 minutes. Relative
to Bregma the coordinates were 1.0 mm anterior, 2.0 mm lateral
and at a depth of 3.0 mm from the skull. To make room for the
sample, the Hamilton syringe was initially inserted 3.50 mm into
the brain and then extracted 0.5 mm. The hole in the skull was
closed with bone wax (Sharpoint, Vancouver, BC) and the incision
was closed with a stapler clip. Mice were monitored carefully and
sacrificed when they displayed symptoms of tumor development
(lethargy, head tilt). T453 cells stably expressing a luciferase
reporter plasmid were transfected with miR-34a or control
oligonucleotides 24 hours prior to injection. Animal experiments
were conducted using protocols approved by the Institutional
Animal Care and Use Committees of Memorial Sloan-Kettering
Cancer Center.
Immunoblotting
Immunoblotting was performed using standard protocols with
the following antibodies: MET (Cell Signaling, Danvers, MA,
25H2) 1:1000; NOTCH1 (Cell Signaling, D6F11) 1:1000;
NOTCH2 (Cell Signaling, D76A6) 1:1000; CDK6 (Cell Signaling,
DCS83) 1:2000; PDGFRA (Cell Signaling) 1:1000; PI3 Kinase
p85 (Millipore) 1:14000; p-AKT, Ser473 (Cell Signaling, D9E)
1:2000; AKT (Cell Signaling) 1:1000; p-MDM2, Ser166 (Cell
Signaling) 1:1000; p53 (Cell Signaling, 1C12) 1:1000, and b-Actin
(Cell Signaling) 1:10000.
PDGFRA-39UTR reporter assays
Two oligonucleotides encompassing the genomic sequence
surrounding the two proposed miR-34a target site in the 39
UTR of PDGFRA were synthesized (IDT DNA, Coralville, IA): 59
TCGATATGTATATATGTATTTCTATATAGACTTGGAG-
AATACTGCCAAAACATTTATGACAAGCTGTATCACTG-
CCTTCGTTTATATTTTTTTAACTGT and 59 GGCCAC-
AGTTAAAAAAATATAAACGAAGGCAGTGATACAGCTT-
GTCATAAATGTTTTGGCAGTATTCTCCAAGTCTATAT-
AGAAATACATATATACATA. The two oligonucleotides were
annealed, and ligated into the psiCHECK22 vector (Promega,
Madison, WI) using XhoI and NotI sites. TS543 cells were plated
in laminin (Sigma-Aldrich, St. Louis, MO) coated wells and
transfected with the psi-CHECK-2-contruct or the empty psi-
CHECK2 vector using Lipofectamine LTX with Plus (Invitrogen,
Grand Island, NY) according to the manufacturer’s instructions.
After 6 hours, cells were transferred to new wells and transfected
with miRNA mimics using Hiperfect reagent (Qiagen, Valencia,
CA) as described above. One day later, cells were lysed with
Passive Lysis Buffer and assayed for luciferase expression using the
Dual-Luciferase Reporter Assay System (Promega Madison, WI)
according to the manufacturer’s protocol.
miR-34a overexpression microarray analysis
miR-34a and control oligonucleotide was transfected into
TS543 cells in triplicate experiments. After 3 days, RNA was
isolated and expression analyses were performed using Illumina
HT-12 bead array. The microarray dataset was normalized using
a variance stable normalization (VSN) procedure in the ‘lumi’
package from the Bioconductor framework [19]. Differential
mRNA expression between miR-34a and control transfected
samples was determined using the moderated t-statistic from the
‘limma’ Bioconductor package [20]. To systematically evaluate
which 39UTR motifs best explain mRNA down-regulation after
Figure 6. miR-34a repression in proneural GBM is likely p53-independent. A) Data from TCGA show that miR-34 expression is
downregulated in proneural tumors in both p53 wild-type and p53 mutant subsets. B) KP cells were treated with imatinib (I) or DMSO (D) over
48 hours. Levels of p53, p-AKT, AKT, and p-MDM2 were determined by immunoblotting. ***, P,0.0001.
doi:10.1371/journal.pone.0033844.g006
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parametric rank-based statistic to perform an exhaustive and
unbiased assessment of the correlation of mRNA 39UTR word
occurrences and the change in gene expression after miR-34a
transfection [21]. In this analysis, genes were sorted by their
expression change after transfection of miR-34a, and the
association with down-regulation was tested for all words of length
5–7 (N=21 504) by comparing to a null model based on
dinucleotide shuffled 39UTR sequences and random permutations
of the ordered list of mRNAs (FIG. S3). The microarray data has
been deposited in the public database Gene Expression Omnibus
(GEO) under accession number GSE34242.
TCGA GBM data
GBM miRNA and mRNA expression datasets (level 3) were
obtained from the TCGA data portal (http://tcga-data.nci.nih.
gov/tcga). The integrated dataset, having both miRNA and
mRNA expression data, comprised 341 samples (TCGA sample
IDs listed in Table S1). This dataset was used for testing pairwise
association of miRNA and mRNA expression. Analysis relating to
GBM subtypes was restricted to the 191 GBM tumor samples,
which had miRNA expression data and were previously classified
by the TCGA consortium [3]. This set comprised 55 proneural
samples, 28 neural, 52 classical, and 56 mesenchymal samples
(TCGA sample IDs listed in Table S1). For analysis relating to p53
mutation status of the tumor samples, TP53 mutation data was
obtained for the same 199 samples from the cBio Cancer
Genomics Portal (www.cbioportal.org/public-portal).
MicroRNA target prediction
MicroRNAs predicted to target PDGFRA and predicted target
genes of miR-34a were determined from the intersection of
miRNA target predictions from miRanda (miRSVR score less
than 20.1) [22] and TargetScan 5.1 (context score less than 0)
[23].
Other statistical analyses
Pairwise association of miRNA and mRNA expression was
evaluated by the non-parametric Spearman correlation coefficient
and the associated p-value was determined by the R statistical
software framework (http://www.r-project.org/). Differential
miRNA expression between two groups of samples was deter-
mined using the non-parametric Wilcoxon rank-sum test (one-
tailed test) in the R statistical software framework.
Supporting Information
Figure S1 Validation of miR-34a expression in GBM
cells. miR-34a expression measured by TaqMan 24 hours
following transfection of 100 nM miR-34a or negative control
microRNA to TS543 and TS600 cells.
(TIF)
Figure S2 In proneural TS543 cells, miR-34a has
minimal repressive effects on other known GBM
targets. TS543 cells were transfected with either miR-34a or
control oligonucleotides for 24 hours, and MET, CDK6, and
NOTCH2 protein levels were measured by immunoblotting.
(TIF)
Figure S3 39UTR motif analysis after miR-34a overex-
pression. We systematically analyzed all words of length 5–7
(N=21 504) for overrepresentation in down-regulated mRNAs
after miR-34a transfection. Consistent with many previous studies
of miRNA overexpression, the word most correlated with down-
regulation was the seed site complementary to mature miR-34a
bases 2–7. The figure shows the top-10 words most correlated with
down-regulation. Word correlation Z-score, rank and estimated
false discovery rate are indicated in columns to the right of each
word. Capital letters highlight the words matching the seed region
(bases 2–8) of the miRNA. Five words (shown in grey) did not align
with the miR-34a sequence.
(TIF)
Table S1 TCGA sample IDs of samples used in this study.
(XLSX)
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